Avanos Medical, Inc.
AVNS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $688 | $673 | $684 | $745 |
| % Growth | 2.2% | -1.6% | -8.1% | – |
| Cost of Goods Sold | $307 | $294 | $290 | $365 |
| Gross Profit | $381 | $380 | $394 | $380 |
| % Margin | 55.4% | 56.4% | 57.6% | 51% |
| R&D Expenses | $26 | $27 | $31 | $32 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $315 | $288 | $323 | $261 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $341 | $315 | $352 | $293 |
| Operating Income | $40 | $65 | $42 | $87 |
| % Margin | 5.8% | 9.7% | 6.1% | 11.7% |
| Other Income/Exp. Net | -$443 | -$73 | -$15 | -$80 |
| Pre-Tax Income | -$403 | -$8 | $27 | $7 |
| Tax Expense | -$17 | $2 | $5 | $1 |
| Net Income | -$392 | -$62 | $51 | $6 |
| % Margin | -57% | -9.2% | 7.4% | 0.8% |
| EPS | -8.53 | -1.33 | 1.08 | 0.13 |
| % Growth | -541.4% | -223.1% | 730.8% | – |
| EPS Diluted | -8.53 | -1.33 | 1.07 | 0.13 |
| Weighted Avg Shares Out | 46 | 47 | 47 | 48 |
| Weighted Avg Shares Out Dil | 46 | 47 | 47 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $3 | $1 | $0 |
| Interest Expense | $12 | $15 | $10 | $3 |
| Depreciation & Amortization | $46 | $44 | $41 | $38 |
| EBITDA | -$346 | $51 | $78 | $49 |
| % Margin | -50.2% | 7.5% | 11.4% | 6.6% |